Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Metrics to compare | NVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVAXPeersSector | |
---|---|---|---|---|
P/E Ratio | 2.5x | −4.5x | −0.5x | |
PEG Ratio | 0.01 | 0.02 | 0.00 | |
Price/Book | −16.0x | 3.7x | 2.6x | |
Price / LTM Sales | 1.0x | 9.3x | 3.2x | |
Upside (Analyst Target) | - | 45.2% | 41.6% | |
Fair Value Upside | Unlock | 8.3% | 6.0% | Unlock |